EpiPen maker says it will market generic version of allergy RX

Henrietta Brewer
September 1, 2016

The senators said Mylan's near monopoly on the epinephrine auto-injector market has allowed it to increase prices well beyond increases in manufacturing costs. Some noted that even at $300, the generic would still be triple the price of the EpiPen in 2007, when Mylan acquired the product and began steadily raising its price, with the increases accelerating in recent years. He says the company made contributions to Wisconsin legislators.

According to Mylan's website, the program has provided more than 700,000 free epinephrine auto-injectors to schools since 2012.

"We had to decide whether we are going to pay our mortgage or auto note", said Germaine Duncan.

".it's very much, as far as a business practice, is like selling basic necessities at inflated prices during a national disaster".

The senators - 19 Democrats and Independent Sen.

The revelation came Monday as the US House Committee on Oversight and Government Reform launched a probe into the drug manufacturer.

EpiPens are used in emergencies to stop potentially fatal allergic reactions to insect bites and stings, and foods like nuts and eggs. In making generic EpiPens available within weeks, as Mylan said it plans to do, it's beating its competitor to the punch. "Given that the $300 generic and $600 branded EpiPen are functionally equivalent, how does Mylan justify the higher price of the branded EpiPen?".

"Alaskans want to hear directly from the company, under oath, exactly how a 400 percent or more price increase for an off-patent medication is justifiable", she said in statement accompanying the release of the letter.

On Monday, the committee's chair, Rep. Jason Chaffetz of Utah, and ranking member Rep. Elijah Cummings of Maryland, sent Mylan CEO Heather Bresch a letter requesting documents related to the company's 500% price hike of the EpiPen since 2007.

"It is illegal for consumers covered under Medicare or Medicaid to use the savings card, nor can these consumers access EpiPens through the patient assistance program", Warren wrote.

Two companies, AUVI-Q and TwinJect, have recalled their epi injectors after having issues with dosage and the device.

Despite its second move in five days to make EpiPens more affordable for consumers, maker Mylan N.V. still faces condemnation from critics who accused it of price-gouging.

Mylan will continue to sell EpiPen and continue to offer a $300 discount to certain families that qualify for assistance based on their income levels.

Other reports by iNewsToday